Recent Updates
Recently added Catalysts

QIV-HD by

Phase 1

Influenza | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Apr 4, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment175
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03233217Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 YearsPHASE1 COMPLETED 175Sep 15, 2017Nov 28, 2017Apr 4, 20222 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Immediate Unsolicited Adverse Events (AE) After Vaccination
Within 30 minutes after vaccination

An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of symptom and/or onset post-vaccination. Unsolicited AEs includes both serious and non-serious unsolicited AEs. A serious adverse event is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.

Number of Participants With Solicited Injection Site and Systemic Reactions
Within 7 days after vaccination

A solicited reaction was an adverse reaction observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited injection site reactions: pain, erythema, swelling, induration, and bruising. Solicited systemic reactions: fever, headache, malaise, myalgia, and shivering.

Number of Participants With Unsolicited Adverse Events After Vaccination
Within 28 days after vaccination

An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of symptom and/or onset post-vaccination. Unsolicited AEs included both serious and non-serious unsolicited AEs. A serious adverse event is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Number of Participant With Serious Adverse Events (SAEs) After Vaccination
Up to 6 months after vaccination

An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Secondary Endpoints
Cohort 2: Geometric Mean Titers (GMTs) of Influenza Antibodies Following Vaccination With QIV-HD or QIV-SD
Day 0 (pre-vaccination) and Day 28 (post-vaccination)
Cohort 2: Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies Following Vaccination With QIV-HD or QIV-SD
Day 0 (pre-vaccination) and Day 28 (post-vaccination)
Cohort 2: Percentage of Participants Achieving Seroconversion Against Antigens Following Vaccination With QIV-HD or QIV-SD
Day 28 (post-vaccination)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Cohort 1: QIV-HD by IMEXPERIMENTALParticipants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
Cohort 1: QIV-HD by SCEXPERIMENTALParticipants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
Cohort 2: QIV-HD by IMEXPERIMENTALParticipants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
Cohort 2: QIV-HD by SCEXPERIMENTALParticipants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
Cohort 2: QIV-SD by SCACTIVE_COMPARATORParticipants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
Interventions
NameTypeDescription
QIV-HD by IMBIOLOGICALIM, injected into the upper arm (deltoid area)
QIV-SD by SCBIOLOGICALSC, injected into the upper arm (posterior region)
QIV-HD by SCBIOLOGICALSC, injection into the upper arm (posterior region)
Unlock Study Design Details
Eligibility Criteria
Age Range65 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Aged \>= 65 years on the day of inclusion. * Informed consent form has been signed and dated. * Able to attend all scheduled visits and to comply with all study procedures. Exclusion Criteria: * Participation at the time of study enrollment (or in the 4 weeks preceding the s...

Countries:Japan
Unlock Eligibility Criteria